Phase Ia clinical trial of ATH-63 in patients with Ulcerative Colitis and Crohn's Disease
Latest Information Update: 31 Mar 2023
At a glance
- Drugs ATH 063 (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Athos Therapeutics
- 29 Mar 2023 According to an Athos Therapeutics media release, the company has been granted a CTN acknowledgement from the Australian Therapeutic Goods Administration and has received Human Research Ethics Committee ("HREC") approval to commence this trial in Australia.
- 15 Nov 2021 According to an Athos Therapeutics media release, company announced completion of an oversubscribed $15MM Series A financing, The funding will be used to advance this trial.
- 15 Oct 2021 New trial record